Transscleral and suprachoroidal drug delivery

Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems

Volumn , Issue , 2012, Pages 179-190

  Berezovsky, Damian E ^a   Edelhauser, Henry F ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885001273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12950     Document Type: Chapter

References (44)

1. Congdon N, O’Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. Apr 2004;122(4):477-485.
2. Tachikawa M, Ganapathy V, Hosoya K-i. Systemic route for retinal drug delivery: Role of the blood-retinal barrier. In Drug Product Development for the Back of the Eye, Kompella UB, Edelhauser HF, eds. Vol 2, 85-109, Springer: New York, 2011.
3. Abouammoh M, Sharma S. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol. May 2011;22(3):152-158.
4. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevaci-zumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. Aug 2011;27(4):373-377.
5. Lee SS, Ghosn C, Yu Z et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. Apr 2010;51(4):2135-2138.
6. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: Thickness and sur-face area. Am J Ophthalmol. Feb 1998;125(2):237-241.
7. Alm A, Nilsson SF. Uveoscleral outflow-A review. Exp Eye Res. Apr 2009;88(4): 760-768.
8. Robinson MR, Lee SS, Kim H et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. Mar 2006;82(3):479-487.
9. Kao JC, Geroski DH, Edelhauser HF. Transscleral permeability of fluorescent-labeled antibiotics. J Ocul Pharmacol Ther. Feb 2005;21(1):1-10.
10. Kim ES, Durairaj C, Kadam RS et al. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. May 2009;26(5):1155-1161.
11. Shuler RK, Jr., Dioguardi PK, Henjy C, Nickerson JM, Cruysberg LP, Edelhauser HF. Scleral permeability of a small, single-stranded oligonucleotide. J Ocul Pharmacol Ther. Apr 2004;20(2):159-168.
12. Cruysberg LP, Nuijts RM, Geroski DH, Koole LH, Hendrikse F, Edelhauser HF. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery sys-tem. J Ocul Pharmacol Ther. Dec 2002;18(6):559-569.
13. Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM, Jr., Edelhauser HF. Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release. May 20 2003;89(3):409-417.
14. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. Nov 1999;40(12):3054-3058.
15. Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM, Jr., Edelhauser HF. Transscleral diffusion of carboplatin: An in vitro and in vivo study. Arch Ophthalmol. Aug 2002;120(8):1069-1074.
16. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci. Dec 1998;87(12):1479-1488.
17. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: Influence of lipophilicity and the Choroid-Bruch’s layer. Invest Ophthalmol Vis Sci. Oct 2006;47(10): 4513-4522.
18. Jiang J, Geroski DH, Edelhauser HF, Prausnitz MR. Measurement and prediction of lat-eral diffusion within human sclera. Invest Ophthalmol Vis Sci. Jul 2006;47(7):3011-3016.
19. Jani AR, Kim ES, Berezovsky DE, Kadam R, Kompella UB, Edelhauser HF. Scleral uptake and extended release of prostaglandin analogs: Bimatoprost, latanoprost, and travoprost in an in vitro model. Invest Ophthalmol Vis Sci. Apr, 2009;50(5):5967.
20. Mora P, Eperon S, Felt-Baeyens O et al. Trans-scleral diffusion of triamcinolone aceton-ide. Curr Eye Res. May 2005;30(5):355-361.
21. Lee SJ, Kim ES, Geroski DH, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci. Oct 2008;49(10):4506-4514.
22. Cruysberg LP, Nuijts RM, Gilbert JA, Geroski DH, Hendrikse F, Edelhauser HF. In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant. Curr Eye Res. Aug 2005;30(8):653-660.
23. Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, Edelhauser HF. Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina. Oct 2004;24(5):776-782.
24. Van Quill KR, Dioguardi PK, Tong CT et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. Jun 2005;112(6):1151-1158.
25. Tsui JY, Dalgard C, Van Quill KR et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. Feb 2008;49(2):490-496.
26. Kim ES, Berglin L, Morohoshi K, Geroski DH, Edelhauser HF. In vitro diffusion of avastin (bevacizumab) across human sclera. ARVO Meeting Abstracts. Apr 11, 2009;50(5):5988.
27. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. May 2007;48(5):2230-2237.
28. Berezovsky DE, Patel SR, McCarey BE, Edelhauser HF. In vivo ocular fluorophotom-etry: Delivery of fluoresceinated dextrans via transscleral diffusion in rabbits. Invest Ophthalmol Vis Sci. 2011;52(10):7038-7045.
29. Ambati J, Gragoudas ES, Miller JW et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. Apr 2000;41(5):1186-1191.
30. Brubaker RF, Pederson JE. Ciliochoroidal detachment. Surv Ophthalmol. Mar-Apr 1983;27(5):281-289.
31. Pederson JE, Gaasterland DE, MacLellan HM. Experimental ciliochoroidal detach-ment: Effect on intraocular pressure and aqueous humor flow. Arch Ophthalmol. Mar 1979;97(3):536-541.
32. Chu TG, Green RL. Suprachoroidal hemorrhage. Surv Ophthalmol. May-Jun 1999;43(6):471-486.
33. Edmund J, Gregersen E. Experimental detachment of the choroid: A new possibility of treatment in retinal detachment. Acta Ophthalmol (Copenh). 1964;42:269-276.
34. Alexandrakis G, Chaudhry NA, Liggett PE, Weitzman M. Spontaneous suprachoroidal hemorrhage in age-related macular degeneration presenting as angle-closure glaucoma. Retina. 1998;18(5):485-486.
35. Einmahl S, Savoldelli M, D’Hermies F, Tabatabay C, Gurny R, Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. May 2002;43(5):1533-1539.
36. Hou J, Tao Y, Jiang YR, Wang K. In vivo and in vitro study of suprachoroidal fibrin glue. Jpn J Ophthalmol. Nov 2009;53(6):640-647.
37. Olsen TW, Feng X, Wabner K et al. Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment. Am J Ophthalmol. Nov 2006;142(5):777-787.
38. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch’s membrane. Prog Retin Eye Res. Jan 2010;29(1):1-18.
39. Olsen TW, Feng X, Wabner K, Csaky K, Pambuccian S, Cameron JD. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci. Jun 2011;52(7):4749-4756.
40. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. Jan 2011;28(1):166-176.
41. Patel SR, Bergman L, Berglin LC et al. Surface area coverage of suprachoroidal injec-tions using a hollow microneedle in fresh human globes. ARVO Meeting Abstracts. Apr 22, 2011;52(6):3255.
42. Mansoor S, Patel SR, Tas C, Grossniklaus HE, Edelhauser HF, Prausnitz MR. Pharmacokinetics and biodistribution of triamcinolone acetonide following supracho-roidal injection into the rabbit eye in vivo using a microneedle. ARVO Meeting Abstracts. Apr 22, 2011;52(6):6585.
43. Berezovsky DE, Patel SR, McCarey BE, Grossniklaus HE, MR, Edelhauser HF. In vivo evaluation of fluorescent microparticles injected in the rabbit suprachoroidal space using hollow microneedles. ARVO Meeting Abstracts. Apr 22, 2011;52(6):2058.
44. Patel SR, Berezovsky D, McCarey BE, Nickerson JM, Edelhauser HF, Prausnitz MR. Intraocular pharmacokinetics of suprachoroidal drug delivery administered using hol-low microneedles. Invest Ophthalmol Vis Sci. Apr, 2010;51(5):3796.